PMID-32621722 – Selank Cytokines Under Social Stress
Yasenyavskaya AL et al., "Effect of Selank on Cytokine Concentration Under Social Stress Conditions," Curr Rev Clin Exp Pharmacol, 2021;16(2):162-167.
Quick Reference
| Property | Value |
|---|---|
| PMID | 32621722 |
| DOI | 10.2174/1574884715666200704152810 |
| Year | 2021 |
| Journal | Current Reviews in Clinical and Experimental Pharmacology |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Rats subjected to social stress paradigm |
| Peptide(s) Studied | Selank |
Key Findings
- Selank decreased pro-inflammatory cytokine concentrations (IL-1β and IL-6) in socially stressed rats
- Treatment restored anti-inflammatory marker IL-4 levels, normalizing the Th1/Th2 cytokine balance disrupted by chronic social stress
- Results demonstrate dual anxiolytic-immunomodulatory activity consistent with Selank's origin as a tuftsin analogue, confirming that its effects extend beyond the nervous system to immune regulation
Study Design
Rats were subjected to a chronic social stress model to induce anxiety-like behavior and immune dysregulation. Selank was administered and cytokine concentrations (IL-1β, IL-6, IL-4) were measured in comparison to stressed and unstressed controls to characterize the peptide's immunomodulatory effects under stress conditions.
Limitations
- Animal model — social stress paradigm may not fully replicate human psychosocial stress
- Limited cytokine panel assessed; broader immune profiling would strengthen conclusions
- Mechanism of immune modulation (direct vs. indirect via stress axis) not fully delineated
Clinical Relevance
This study reinforces Selank's unique dual-action profile as both an anxiolytic and immunomodulator, supporting its therapeutic potential for conditions where psychological stress drives immune dysfunction — a common clinical scenario in anxiety disorders, chronic stress, and autoimmune flares.
Related
#research #animal-in-vivo #evidence-level-V